TScan Therapeutics Inc. (TCRX)
| Bid | 1.01 |
| Market Cap | 80.08M |
| Revenue (ttm) | 1.32M |
| Net Income (ttm) | -59.73M |
| EPS (ttm) | -1.14 |
| PE Ratio (ttm) | -1.24 |
| Forward PE | -2.06 |
| Analyst | Buy |
| Ask | 1.67 |
| Volume | 546,769 |
| Avg. Volume (20D) | 388,611 |
| Open | 1.29 |
| Previous Close | 1.35 |
| Day's Range | 1.27 - 1.43 |
| 52-Week Range | 1.28 - 9.69 |
| Beta | 0.91 |
About TCRX
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors....
Analyst Forecast
According to 6 analyst ratings, the average rating for TCRX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 606.71% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
TScan Therapeutics: Finding Their Footing After An Eventful ASH MeetingTScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are...
